2025 Menopause Guidelines: Vaginal Hormones, Shared Decision-Making, and Women's Health

New AUA Guidelines for Genitourinary Syndrome of Menopause (GSM)

• 🚀 The American Urologic Association (AUA) has released groundbreaking 2025 guidelines for Genitourinary Syndrome of Menopause (GSM), marking the first guideline from the AUA focused on women's sexual health.
• 💡 These guidelines are the result of a multi-year, multidisciplinary effort involving urologists, urogynecologists, patient advocates, and experts from the Menopause Society and IS-Wish.
• ✅ The guidelines are described as bold, simple, unapologetic, and evidence-based, aiming to revolutionize care for women experiencing GSM.

Key Principles and Recommendations

• 🎯 A central tenet of the new guidelines is shared decision-making, emphasizing that treatment plans should be collaborative between patient and provider, mirroring practices for men's health.
• 🔑 The guidelines present a toolbox approach to GSM treatment, moving away from a strict first-line, second-line, third-line therapy model.
• 💡 Vaginal hormones (estrogen and androgens like DHEA) are strongly recommended as safe and effective for treating GSM symptoms, including pain with intercourse, overactive bladder, urinary urgency, and recurrent urinary tract infections (UTIs).
• ⚠️ The guidelines explicitly state there is no evidence linking low-dose vaginal estrogen to breast cancer and recommend its use even in patients with a history of breast cancer, within a shared decision-making framework.
• 🔬 Laser-based therapy for GSM is noted as lacking sufficient data for recommendation, though it can be considered in shared decision-making with patients.

Addressing Challenges and Expanding Access

• 🗣️ The guidelines address the marketing problem in women's health, noting that incorrect labeling on vaginal estrogen products, based on misinterpretations of systemic estrogen data, hinders prescribing.
• 🏥 There's a call for broader clinician involvement beyond gynecologists, including primary care, internal medicine, and infectious disease specialists, to manage GSM, as it affects 50% of the population.
• 🌍 The guidelines and related resources are freely accessible online, empowering patients to bring this information to their healthcare providers.
• 💻 Telemedicine platforms are highlighted as a way to increase access to vaginal estrogen prescriptions for those facing barriers to in-person care.

The Impact and Future of GSM Care

• 📈 Studies presented at the AUA meeting show significant risk reductions in hospitalization (22%), sepsis (51%), and mortality (73%) for women on vaginal estrogen, with potential Medicare savings of billions annually.
• 🩺 Vaginal estrogen is presented as a lifelong therapy, akin to brushing teeth or wearing a seatbelt, for maintaining genital and urinary health and sexual function.
• 🌟 The evolution of terminology from